Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population (Q44469560)

3 December 2017

title

Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population (English)

1 reference

3 December 2017

1 reference

Joyce Noah-Vanhoucke

1 reference

3 December 2017

Linda E Green

1 reference

3 December 2017

Tuan A Dinh

1 reference

3 December 2017

Peter Alperin

1 reference

3 December 2017

Robert A Smith

1 reference

3 December 2017

language of work or name

English

0 references

publication date

14 March 2011

1 reference

3 December 2017

1 reference

3 December 2017

volume

117

1 reference

3 December 2017

1 reference

3 December 2017

page(s)

3322-3331

1 reference

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Chemoprevention: drug pricing and mortality: the case of tamoxifen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Tamoxifen treatment and gynecologic side effects: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Breast Cancer Surveillance Consortium: a national mammography screening and outcomes database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Longitudinal trends in mammographic percent density and breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Validation of the Gail et al. model for predicting individual breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Benign breast disease and the risk of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Estimated case fatality rate of pulmonary embolism, 1979 to 1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Overview of the main outcomes in breast-cancer prevention trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Medical expenditures during the last year of life: findings from the 1992-1996 Medicare current beneficiary survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Cost-effectiveness of digital mammography breast cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Tamoxifen for breast cancer prevention: a framework for clinical decisions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

The use of QALYs in health care decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Adherence beliefs among breast cancer patients taking tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Patient reluctance toward tamoxifen use for breast cancer primary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Predicting risk of breast cancer in postmenopausal women by hormone receptor status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Outcomes of Tamoxifen Chemoprevention for Breast Cancer in Very High-Risk Women: A Cost-Effectiveness Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

Prescription of tamoxifen for breast cancer prevention by primary care physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Screening mammography in British Columbia: 1988-1993

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Risk-adjusted cancer-incidence rates (United States)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Adherence to endocrine therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25926

7 January 2021

Identifiers

DOI

10.1002/CNCR.25926

1 reference

3 December 2017

1 reference